Q2 2025 Elanco Animal Health Inc Earnings Call Transcript
Key Points
- Elanco Animal Health Inc (ELAN) reported 8% organic constant currency growth, exceeding the high end of guidance for revenue, adjusted EBITDA, and adjusted EPS.
- The company achieved strong cash generation, with a net leverage ratio improvement to 4.0 times, and raised its net leverage target for year-end to 3.8 to 4.1 times.
- Innovation revenue outperformed expectations, with a first-half revenue of $420 million, leading to an increased full-year expectation of $720 million to $800 million.
- US Pet Health led the quarter with an 11% increase, driven by both Vet clinic and US retail, marking 8 consecutive quarters of underlying growth.
- Elanco Animal Health Inc (ELAN) is focusing on innovation and productivity, with initiatives like Elanco Ascend expected to drive additional efficiencies and capabilities in key areas.
- Gross margin decreased by 90 basis points to 57.3% due to inflation and higher manufacturing costs.
- Operating expenses increased by 11% compared to the same period last year, impacting adjusted EBITDA flow-through.
- The company experienced pre-tariff customer buying primarily in China, which could affect future revenue comparisons.
- Adjusted EBITDA decreased by $37 million year-over-year, and adjusted EPS decreased by $0.04 year-over-year.
- There are potential risks related to tariffs and economic slowdown, although Elanco Animal Health Inc (ELAN) has mitigation plans in place.
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health second-quarter 2025 earnings conference call. (Operator Instructions). I would now like to hand the call over to Tiffany Kanaga, Head of Investor Relations. You may begin your conference.
Good morning. Thank you for joining us for Elanco Animal Health's second quarter 2025 earnings call. I'm Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer; Robert VanHimbergen, our Chief Financial Officer; and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com.
Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
